Please login to the form below

Not currently logged in
Email:
Password:

bortezomib

This page shows the latest bortezomib news and features for those working in and with pharma, biotech and healthcare.

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

However, Sanofi is currently evaluating Sarclisa in combination with Velcade (bortezomib), Revlimid and dexamethasone in newly diagnosed multiple myeloma patients who are not eligible for transplant.

Latest news

More from news
Approximately 5 fully matching, plus 93 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • What does the future hold for Light-chain Amyloidosis?

    In the absence of approved therapies, the treatment strategy being adopted was very much aligned with that recommended for Multiple Myeloma, with Velcade (bortezomib), used in combination with cyclophosphamide and dexamethasone

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....